anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture before the random assignment to DS arm. Eight Digital Stories Intervention (4 patient and 4 caregiver stories about hematopoietic stem cell transplantation (HCT) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each).
The healthy-lifestyle control served as the usual care comparison group. For 3 months, participants met monthly with a health educator to discuss topics such as osteoarthritis, obesity, and exercise. Regular phone contact was maintained during months 4-18.
PURPOSE: A composite composition prepared by adding beta-glucan having immunostimulating effect to a composite amino acid composition obtained by acid hydrolysis of keratin is provided. The composite composition increases the growth rate of a fish when used as an additive of feed and protective immunity thereof against diseases. CONSTITUTION: A composite amino acid composition comprises beta-glucan and composite amino acid containing an acid hydrolysate of keratin. The beta-glucan is obtained from yeast, mushroom, cereal and microorganism. The composite amino acid containing an acid hydrolysate of keratin contains below 8% by weight of glutamic acid, below 20% by weight of glycine, below 4% by weight of proline, below 7% by weight of histidine, below 4% by weight of threonine, below 7% by weight of arginine, below 5% by weight of serine and below 20% by weight of betaine. A feed contains 0.2 to 2% by weight of the composite amino acid composition.
PURPOSE: To stabilize a VHP-F VIII product having VIII: C clotting factor (F VIII: C) specific activity as high as >=1,000IU/mg useful for hemophilia A therapy without the need of adding any protein with risk of viral contamination. CONSTITUTION: A solution having F VIII: C activity, pref. a solution derived from human factor VIII in such a form that F VIII: C activity is present in the plasma, VIII: C factor based on the genetic engineering or derivatives therefrom, is formulated with an amino acid (pref. natural amino acid, basic amino acid, esp. arginine or glycine) or salt thereof or derivative therefrom at 0.001-1mol/L and, when appropriate, also with a detergent (pref. nonionic detergent) or organic polymer, thus obtaining the aimed stabilized solution >=1,000IU/mg in F VIII: C specific activity, esp. the objective medicine containing this solution. Furthermore, the medicine may be formulated, other than the above solution, which pharmaceutically compatible stabilizing and/or buffering substance(s) in common use, esp. carbohydrate(s).
The present invention discloses a super antigen immunization gene therapeutic agent of hepatocellular cacer (liver cancer), which belongs to the technology of genetic engineering. The present invention is characterized in that a therapeutic agent carrying out targeting expression in liver cancer cells by super antigen molecules and costimulatory molecules mediated by liver cancer cell specificity regulation sequence is prepared to specifically enhance the immunogenicity of cancer cells and the recognition action of immune effect cells. In human body, the therapeutic agent is transported to the cancer area by an intervention manner to effectively kill the cancer cells. The expression of the two kinds of molecules can be adjusted by regulating the specificity regulation sequence by relevant medicines, and the therapeutic effect can be judged by the self-product level regulated by the specificity regulation sequence. Simultaneously, the therapeutic agent carries out adoptive immunotherapy by inducing self-T cell in vitro to assist the treatment in the human body so as to enhance the therapeutic effect, treat the metastasis and prevent the relapse. The therapeutical agent has the characteristics of safety, targeting, controllability, high efficiency on killing cancer, etc. The present invention is a liver cancer immunization gene therapeutic agent which good prospects.
It is intended to provide a method of preventing or relieving reperfusion-induced cell death (apoptotic cell death) of myocardial cells due to postischemic reperfusion; a reperfusion-induced cell death (apoptotic myocardial cell death) inhibitor; and therapeutic drug or a preventive drug for diseases caused by reperfusion-induced cell death (apoptotic cell death) which contains the reperfusion-induced cell death inhibitor. Namely, reperfusion-induced cell death (apoptotic cell death) can be significantly inhibited by administering a VSOR Cl channel blocker or an ROS scavenger to myocardial cells, which have been subjected to an ischemic treatment,. during reperfusion. As the VSOR Cl channel blocker, it is preferable to use, for example, DIDS or NPPB. As the ROS scavenger, it is preferable to use, for example, Tiron, catalase or NAC. Thus, various diseases caused by reperfusion-induced cell death can be effectively treated or prevented.
PURPOSE:The titled preparation that is made by making leupeptin included in a liposome composed of lecithin, cholesterol and brain sulfatide, thus showing remarkable curing effect for demyelinating diseases. CONSTITUTION:Lecithin such as yolk lecithin, cholesterol and brain sulfatide (galactocerebroside-3'-sulfate) such as bovine brain sulfatide are dissolved in an appropriate solvent such as chloroform, then the solvent is removed, and an aqueous solution of leupeptin (acetyl-L-leucyl-L-leucyl-L-argininal), preferably of  0.05- 5% concentration is added. Then, when necessary, the mixture is subjected  to ultrasonic treatment to give an aqueous suspension of liposome including  leupetin. The amounts of the cholesterol and brain sulfatide are 10-25pts.wt.  and 10-30pts.wt. per 100pts. of the lecithine, respectively.
The problem addressed by the present invention is to provide a new intraocular pressure lowering agent and a new agent for treating or preventing glaucoma or ocular hypertension. The present invention also addresses the problem of providing a new use for cyclic phosphatidic acid derivatives and salts thereof. The present invention provides an intraocular pressure lowering agent, a new agent for treating or preventing glaucoma or ocular hypertension, and a ROCK inhibitor that contain as an active ingredient a compound represented by formula (1). (In the formula, R represents linear or branched alkyl group having 1-30 carbon atoms, a linear or branched alkenyl group having 2-30 carbon atoms, or a linear or branched alkynyl group having 2-30 carbon atoms, each group optionally containing a cycloalkane ring or an aromatic ring. X and Y independently represent an oxygen atom or a methylene group, provided that X and Y do not represent a methylene group at the same time. M represents a hydrogen atom or an alkali metal atom.)
BACKGROUND: Abdominoplasty procedures continue to evolve because combining techniques such as suction-assisted lipectomy or direct subscarpal lipectomy have proven to be powerful adjuncts to achieve optimal aesthetic results. However, concern has been expressed about combining techniques simultaneously given the potential to damage the vascularity of the abdominoplasty flap.
OBJECTIVES: The aim of this study was to assess the safety and efficacy of simultaneous direct subscarpal lipectomy combined with liposuction in abdominoplasty patients.
METHODS: A 4-year retrospective review of consecutive abdominoplasties (n = 200) performed by a single surgeon was conducted. Liposuction of the abdominal flap and flanks was performed in all patients. After raising the abdominoplasty flap, undermining was performed to just beyond the xyphoid, the lower rib margins superiorly, and the anterior axillary line laterally. Fat deep to Scarpa's fascia was then removed by direct tangential excision in all zones of the abdominal flap.
RESULTS: The patients had a mean age of 42.19 years and BMI of 28.10 kg/m2; the mean follow-up time was 7 months. Seroma occurred in 13 patients (6.5%), superficial wound dehiscence treated with local wound care in 16 patients (8%), hypertrophic scarring in 16 patients (8%), partial umbilical necrosis in 1 patient (0.5%), and partial umbilical epidermolysis in 6 patients (3%). No patients experienced major or minor full-thickness tissue loss. No patients needed reoperation.
CONCLUSIONS: Simultaneous direct excision of subscarpal fat with liposuction of the abdomen and flanks does not appear to subject any zone of the abdominoplasty flap to increased risks of vascular compromise. No flap necroses were observed. The technique described is safe and may provide superior abdominoplasty results.
Citalopram HBr is an orally administered selective serotonin reuptake inhibitor (SSRI) with a chemical structure unrelated to that of other SSRIs or of tricyclic, tetracyclic, or other available antidepressant agents. Citalopram HBr is a racemic bicyclic phthalane derivative designated (±)-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile, HBr with the following structural formula:

The molecular formula is C20H22BrFN2O and its molecular weight is 405.35.

Citalopram HBr, USP occurs as a fine, white to off-white powder.Citalopram HBr is sparingly soluble in water and soluble in ethanol. Citalopram hydrobromide is available as tablets.

Citalopram hydrobromide 10 mg tablets are film-coated, round shaped tablets containing citalopram HBr in strengths equivalent to 10 mg citalopram base. Citalopram hydrobromide 20 mg and 40 mg tablets are film-coated, oval shaped, scored tablets containing citalopram HBr in strengths equivalent to 20 mg or 40 mg citalopram base. The tablets also contain the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, starch, croscarmellose sodium, copovidone, magnesium stearate, hypromellose, titanium dioxide, ferric oxide red, ferric oxide yellow, glycerin, and polyethylene glycol.
Conduct and psychiatric disorders are found among a higher proportion of people with mental retardation than among people who are not mentally retarded. Among the many different treatment approaches to conduct disorder are drug therapy, behavioral treatment, psychotherapy, and training for cognitive and social skills. Studies have suggested that neuroleptic drugs, such as risperidone, may be beneficial in treating conduct disorder in mental retardation. This is a randomized, double-blind, placebo-controlled study to evaluate the effectiveness of risperidone (0.02 to 0.06 mg/kg/day) compared with placebo in the treatment of children 5 to 12 years of age with mild, moderate, or borderline mental retardation, and who display destructive behaviors. The study has two phases: a run-in phase of 1 week and a treatment phase of 6 weeks. Patients receive placebo to be taken orally once a day during the first week (run-in). On the basis of scores on the Nisonger Child Behavior Rating Form (N-CBRF) and the Vineland Adaptive Behavior Scale after the first week, patients either continue in the double-blind treatment phase or discontinue the study. During the treatment phase patients receive an oral solution of risperidone (increasing gradually to a maximum dose of 0.06 mg/kg) or placebo to be taken once daily for 6 weeks. A parent or caregiver evaluates the child's behavior and symptoms at scheduled office visits during the course of treatment. The primary measure of effectiveness is the change in the Conduct Problem subscale of the Nisonger Child Behavior Rating Form (N-CBRF) at end of treatment compared with baseline. Additional assessments of effectiveness include: the Aberrant Behavior Checklist (ABC), the Behavioral Problems Inventory (BPI), and the Clinical Global Impression (CGI). Safety assessments include the incidence of adverse events throughout the study; weekly measurement of vital signs (pulse, temperature, blood pressure) and evaluation of the presence and severity of extrapyramidal symptoms by the Extrapyramidal Symptom Rating Scale (ESRS); and clinical laboratory tests performed both before study initiation and at the end of treatment. The study hypothesis is that risperidone is well tolerated and effective for the treatment of conduct disorder in children aged 5 to 12 years with mild, moderate, or borderline mental retardation. Risperidone oral solution 1 mg/mL or placebo oral solution, once daily on Days 1 and 2 at dose of 0.01 mg/kg body weight. Dose is 0.02 mg/kg on Day 3, increasing gradually to 0.06 mg/kg (maximum) once daily through 6 weeks. Dosage may be increased or decreased at investigator's discretion.
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with a significant proportion of cases occurring in China. Despite advancements in treatment, the prognosis for HCC remains poor due to late diagnosis and high recurrence rates. Minimal Residual Disease (MRD) refers to the presence of residual cancer cells after treatment, which can lead to tumor recurrence. The primary objective of this study is to evaluate the effectiveness of plasma tumor mitochondrial mutations as a biomarker for MRD assessment and recurrence monitoring in patients with resectable HCC. The study hypothesizes that the presence and dynamics of tumor mitochondrial mutations in plasma are associated with the risk of recurrence and overall survival in HCC patients. This is a prospective, observational, single-center study conducted by the Chinese Cooperative Group of Liver Cancer (CCGLC) under the auspices of the Chinese Chapter of International Hepato-Pancreato Biliary Association. The study will involve the collection and analysis of plasma samples from patients with HCC to detect ct-mtDNA mutations before and after surgery. The primary clinical endpoint is the impact of MRD status on progression-free survival (PFS). Secondary endpoints include the influence of surgery on MRD markers, the correlation between postoperative residual tumor molecular burden and PFS, and the ability of MRD detection to predict recurrence earlier than traditional tumor markers or imaging methods. This study seeks to contribute to the field of HCC management by providing a more precise and personalized approach to postoperative MRD assessment and recurrence monitoring. The findings have the potential to improve long-term treatment outcomes and quality of life for patients with HCC.
This is a randomized (study drug assigned by chance), open-label (both physician and patient know the name of the assigned drug), rater-blinded (the person who assesses the condition of the patient does not know the name of the assigned drug), active-controlled, parallel-group, multicenter, prospective international study of paliperidone palmitate versus treatment as usual with oral antipsychotic agents in monotherapy in the prevention of relapse (return of symptoms). Patients who have been recently diagnosed with schizophrenia (within 5 years) and are suffering from a schizophrenic relapse (return of symptoms of schizophrenia) will be enrolled. This study consists of a 2-week initial acute oral treatment phase, followed by a treatment phase (core phase) until relapse or up to maximally 24 months, whichever comes first. Prior to a 2-week oral treatment phase, patients will be randomly (by chance) assigned in a 1:1 ratio to receive treatment with paliperidone palmitate injection (once-monthly) or oral antipsychotic medication (daily). Patients randomized to paliperidone palmitate will first receive oral paliperidone ER once daily for 2 weeks followed by paliperidone palmitate injections at a dose of 150 mg eq. on Day 1, 100 mg eq. on Day 8 both in the deltoid muscle and 75 mg eq. on Day 38 and doses in a dose range of 25 to 150 mg eq. in either the deltoid or the gluteal muscle thereafter. Patients randomized to oral comparator arm will receive oral antipsychotics (haloperidol, paliperidone ER, risperidone, olanzapine, quetiapine or aripiprazole) as per investigator discretion and prescribed according to the label. Total treatment duration is maximally 24 months. During the 24 month treatment phase, investigators will be allowed to flexibly decrease or increase the dose of paliperidone palmitate with one dose level in the range of 25 to 150 mg eq. or the oral antipsychotic in the respective locally approved dose range, all according to the patient's clinical needs. The primary endpoint of the 24-month treatment phase will be the time to relapse. Safety will be monitored by evaluating Adverse Events (AEs), rating of extrapyramidal symptoms (symptoms like abnormal muscle movements, abnormal movements of the tongue or jaw, slow or sustained muscle contractions, muscle spasms, shaking, abnormal movements of the eyes, involuntary muscle contractions, slow movements, or restlessness), vital signs measurements (including heart rate and blood pressure), body weight and physical examination findings. A urine pregnancy test will be performed in females of childbearing potential. Adverse events (unintended, but not necessarily unexpected, results of therapy that can be unpleasant or dangerous), associated concomitant medications, and symptoms of relapse will be recorded as needed.
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide.Early diagnosis improves the prognosis. Protein induced by vitamin K antagonist-II (PIVKA-II), also known as des-γ-carboxyprothrombin (DCP) or acarboxy prothrombin, is an abnormal form of prothrombin induced by vitamin K absence or antagonist-II. The study is intended to evaluate the diagnostic efficiency of AFP-L3 and PIVKA-II. AFP-L3 and PIVKA-II as an effective tumor marker for hepatocellular carcinoma(HCC). Despite the extensive application of PIVKA-II in some hospitals from Vietnam, the diagnostic efficiency including sensitivity, specificity, positive predictive value and negative predictive value still needs more clinical data to evaluate. The research purposes list as follows：1. Determination of changes in AFP-L3 and PIVKA II for HCC.2. Investigating the diagnostic value of AFP-L3 and PIVKA II for HCC. This study is performed at Hanoi Medical University Hospital. Participants including patients with HCC and hepatic hemangioma. All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum samples were tested for PIVKA-II, AFP, AFP-L3 and biochemical indexes including alanine aminotransferase(ALT),aspartate aminotransferase (AST), gamma-glutamyl transferase, HbsAg, Anti HCV, etc.The diagnosis of HCC was based on HCC criteria of Ministry of Public Health of Vietnam. All HCC diagnoses were confirmed at the time of analysis. Stages of tumor is evaluated by Barcelana classification. The Student's t-test (or Mann-Whitney test) was used to compare continuous variables, and the chi-square test (or Fisher's exact test) was used for categorical variables. A receiver operator characteristic (ROC) curve was used to assess the performance characteristic of PIVKA-II,AFP,AFP-L3 measurement.
PURPOSE:To obtain a stable activated vitamin D3 preparation having improved uniformity of the content of the active component by including an activated vitamin D3 in a phase containing gelatin. CONSTITUTION:An activated vitamin D3 is solubilized with a proper nonionic surfactant or an activated vitamin D3 is dissolved in an organic solvent compatible with water (preferably ethanol) and is mixed in an aqueous solution of gelatin to dissolve or disperse the activated vitamin D3 and obtain the objective preparation. The amount of gelatin in the preparation is preferably 1-100,000 pts. especially 100-50,000 pts. per 1 pt of the activated vitamin D3. The stability of the activated vitamin D3 can remarkably be improved by adding 1-100,000 pts., especially 10-50,000 pts. of an amino acid (based on 1 pt. of the activated vitamin D3) to the above preparation.
BACKGROUND: Kawasaki disease (KD) is an acute pediatric vasculitis that can lead to coronary artery aneurysms and severe cardiovascular complications, often presenting with obvious fever in the early stages. In current clinical practice, distinguishing KD from other febrile illnesses remains a significant challenge. In recent years, some researchers have explored the potential of machine learning (ML) methods for the differential diagnosis of KD versus other febrile illnesses, as well as for predicting coronary artery lesions (CALs) in people with KD. However, there is still a lack of systematic evidence to validate their effectiveness. Therefore, we have conducted the first systematic review and meta-analysis to evaluate the accuracy of ML in differentiating KD from other febrile illnesses and in predicting CALs in people with KD, so as to provide evidence-based support for the application of ML in the diagnosis and treatment of KD.
OBJECTIVE: This study aimed to summarize the accuracy of ML in differentiating KD from other febrile illnesses and predicting CALs in people with KD.
METHODS: PubMed, Cochrane Library, Embase, and Web of Science were systematically searched until September 26, 2023. The risk of bias in the included original studies was appraised using the Prediction Model Risk of Bias Assessment Tool (PROBAST). Stata (version 15.0; StataCorp) was used for the statistical analysis.
RESULTS: A total of 29 studies were incorporated. Of them, 20 used ML to differentiate KD from other febrile illnesses. These studies involved a total of 103,882 participants, including 12,541 people with KD. In the validation set, the pooled concordance index, sensitivity, and specificity were 0.898 (95% CI 0.874-0.922), 0.91 (95% CI 0.83-0.95), and 0.86 (95% CI 0.80-0.90), respectively. Meanwhile, 9 studies used ML for early prediction of the risk of CALs in children with KD. These studies involved a total of 6503 people with KD, of whom 986 had CALs. The pooled concordance index in the validation set was 0.787 (95% CI 0.738-0.835).
CONCLUSIONS: The diagnostic and predictive factors used in the studies we included were primarily derived from common clinical data. The ML models constructed based on these clinical data demonstrated promising effectiveness in differentiating KD from other febrile illnesses and in predicting coronary artery lesions. Therefore, in future research, we can explore the use of ML methods to identify more efficient predictors and develop tools that can be applied on a broader scale for the differentiation of KD and the prediction of CALs.
Patients identified as "disorders of consciousness" admitted to UPMC Rehabilitation Institute will be considered for the trial. As patients will not be able to communicate, health care proxy will provide consent. Participants will undergo 3 trials across 5 days within a 10-day period (2-3 hours each ) to assess if they are responding to the device.
Background and Objectives: Our study compared the visual and anatomical outcomes of polypoidal choroidal vasculopathy (PCV) patients receiving intravitreal aflibercept (IVA) with or without photodynamic therapy (PDT) over 12 months. Materials and Methods: This retrospective study was performed for 60 eyes from 60 patients with treatment-naïve PCV. Thirty eyes were treated using IVA monotherapy (IVA group), and thirty eyes were treated using a combination of IVA with PDT (IVA/PDT group). The baseline characteristics, treatment outcomes, and retreatment rates were compared between the two groups over a one-year follow-up period. Results: The best-corrected visual acuity (BCVA) was found to have improved significantly in the IVA/PDT group at every 3-month visit. However, no significant BCVA improvement was observed in the IVA group. A significantly lower retreatment rate and higher dry macula rate were found in the IVA/PDT group than that in the IVA group. In the entire population of the study, a better baseline vision and younger age were associated with better final visual outcomes. Retreatment was associated with poor baseline BCVA and IVA monotherapy. Conclusions: The combination of IVA and PDT may offer superior visual improvement and a higher dry macula rate compared to IVA monotherapy in the treatment of PCV patients while requiring fewer retreatments over 12 months.